

APR 20 2006 10 10 APR 2006

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. SER-107

April 19, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mara Rossi, Thierry Ziegler, Laure Valognes
Filed : April 19, 2006
For : Process for the Purification of IL-18 Binding Protein

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/fes

Attachments: Form PTO/SB/08; copies of cited references.

19 APR 2006

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number		
			Filing Date		
			First Named Inventor		
			Art Unit		
			Examiner Name		
Sheet	1	of	3	Attorney Docket Number	SER-107

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 99/09063 A1	02-25-1999	Yeda Research and Development Co. Ltd	All	
	F2	EP 1 110 969 A1	06-27-2001	Kabukishi, et al.	All	
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APR 19 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known 0372	
		Application Number	
Sheet	2	of	3
		Filing Date	April 19, 2006
		First Named Inventor	Mara Rossi
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	SER-107

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	KIM, S-H. <i>et al.</i> "Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18" <i>Proceedings of the National Academy of Sciences of USA</i> , February 1, 2000, pp. 1190-1195, Vol. 97, No. 3.	
	R2	ALTSCHUL, S.F. <i>et al.</i> "Basic local alignment search tool" <i>J. Mol. Biol.</i> , 1990, pp. 403-410, Vol. 215.	
	R3	ALTSCHUL, S.F. <i>et al.</i> "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <i>Nucleic Acids Research</i> , 1997, pp. 3389-3402, Vol. 25, No. 17.	
	R4	BOSCHETTI, E. <i>et al.</i> "Separation of antibodies by liquid chromatography" <i>Sep. Sci & Tech.</i> 2, 2000, No. 15, pp. 536-632, Academic Press.	
	R5	BOSCHETTI, E. <i>et al.</i> "Bioprocess Tutorial Hydrophobic charge-induction chromatography" <i>Genetic Engineering</i> , July 2000, Vol. 20, No. 13.	
	R6	DEVEREUX, J. <i>et al.</i> "A comprehensive set of sequence analysis programs for the VAX" <i>Nucleic Acids Research</i> , 1984, pp. 387-395, Vol. 12, No. 1.	
	R7	GRANTHAM, R. "Amino acid difference formula to help explain protein evolution" <i>Science</i> , September 6, 1974, pp. 862-864, Vol. 185.	
	R8	NOVICK, D. <i>et al.</i> "Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response" <i>Immunity</i> , January 1999, pp. 127-136, Vol. 10.	
	R9	PEARSON, W.R. <i>et al.</i> "Rapid and sensitive sequence comparison with FASTP and FASTA" <i>Methods in Enzymology</i> , pp. 63-98, Vol. 183.	
	R10	PORATH, J. <i>et al.</i> "Metal chelate affinity chromatography, a new approach to protein fractionation" <i>Nature</i> , December 18, 1975, pp. 598-599, Vol. 258.	
	R11	PORATH, J. <i>et al.</i> "Immobilized metal ion affinity adsorption and immobilized metal ion affinity chromatography of biomaterials. Serum protein affinities for Gel-Immobilized iron and nickel ions" <i>Biochemistry</i> , 1983, pp. 1621-1630, Vol. 22.	
	R12	PUREN, A. J. <i>et al.</i> "Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1β are differentially regulated in human blood mononuclear cells and mouse spleen cells" <i>Proc. Natl. Acad. Sci. USA</i> , March 1999, pp. 2256-2261, Vol. 96.	
	R13	URUSHIHARA, N. <i>et al.</i> "Elevation of serum interleukin-1 levels and activation of kupffer cells in biliary atresia" <i>Journal of Pediatric Surgery</i> , March 2000, pp. 446-449, Vol. 35, No. 3.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number		
			Filing Date		
			First Named Inventor		
			Group Art Unit		
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	SER-107

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	VIGERS, G. P. A. <i>et al.</i> "Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 β " <i>Nature</i> , March 13, 1997, pp. 190-194, Vol. 386.	
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.